Teva established its Australian branch in 2014.
|Teva Pharma Australia Pty Ltd||AUS||website|
| Teva Pharmaceutical Industries Ltd
owns 100% of Teva Pharma Australia Pty Ltd
|Teva Pharma Australia Pty Ltd|
|No assessment data currently available for Teva Pharma Australia Pty Ltd|
|Teva Pharmaceutical Industries Ltd|
In 2018, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of A-.
[Source 2018][More on Climate Change]
This company received a score of 35.9/100 in the Newsweek Green Rankings 2016, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
[Source 2016][More on Sustainability Reporting]
In 2015 this company agreed to pay US$1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil. The settlement stems from charges brought in 2008 against Cephalon Inc, which was acquired by Teva in 2012.
[Source 2015][More on Finance]
|Company Structure||Wholly-owned subsidiary|
|Address||Level 2, 37 Epping Road, Macquarie Park, NSW, 2113, Australia|
|Phone||02 8061 9999|
|Freecall||1800 288 382|